about
Maintenance treatment with antipsychotic drugs for schizophreniaAripiprazole versus other atypical antipsychotics for schizophreniaAripiprazole versus other atypical antipsychotics for schizophreniaQuetiapine versus other atypical antipsychotics for schizophreniaZotepine versus other atypical antipsychotics for schizophreniaRisperidone versus other atypical antipsychotics for schizophreniaHaloperidol versus low-potency first-generation antipsychotic drugs for schizophreniaSecond-generation antipsychotics for major depressive disorder and dysthymiaSecond-generation antipsychotics for anxiety disordersSecond-generation antipsychotics for obsessive compulsive disorderClozapine versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaAripiprazole versus other atypical antipsychotics for schizophreniaZiprasidone versus other atypical antipsychotics for schizophreniaAmisulpride versus other atypical antipsychotics for schizophreniaZotepine versus other atypical antipsychotics for schizophreniaSecond-generation antipsychotic drugs for anxiety disordersQuetiapine versus other atypical antipsychotics for schizophreniaSecond-generation antipsychotic drugs for obsessive compulsive disorderSecond-generation antipsychotic drugs for major depressive disorderSertindole versus other atypical antipsychotics for schizophreniaMaintenance treatment with antipsychotic drugs for schizophreniaSertindole versus other atypical antipsychotics for schizophreniaZiprasidone versus other atypical antipsychotics for schizophreniaOlanzapine versus other atypical antipsychotics for schizophreniaAripiprazole versus other atypical antipsychotics for schizophreniaRisperidone versus other atypical antipsychotics for schizophreniaQuetiapine versus other atypical antipsychotics for schizophreniaZotepine versus other atypical antipsychotics for schizophreniaAmisulpride versus other atypical antipsychotics for schizophreniaClozapine versus other atypical antipsychotics for schizophrenia
P50
Q24197902-F422028F-665B-4ABC-B217-C9FDE2F74A5AQ24200904-5284D550-E2F2-417D-9554-DD914FAF9D1EQ24201232-9F032424-56B4-479E-8DA2-BB37DEBFA7FFQ24202427-39E7D3BE-A0CE-4794-BBE9-9AF48814B3C0Q24234683-34BE9FA4-B537-4390-BF26-612F81DEC1D8Q24234950-57B884E5-D458-4281-9B74-B0C73155E069Q24235300-CF7878AA-6A6B-43BE-81D8-730186213DD3Q24235667-5E1311A4-D46A-4669-89DB-AE89EA14F416Q24235758-009A781D-EB63-4037-896F-5410910F3D20Q24235770-631317C0-6C4C-499C-94C1-D5D9D1B7DC81Q24236422-182F184C-2BFC-42BD-A6C2-64696AE13BE0Q24236545-1D18E7D3-FFE2-42A0-9CBA-CCE88CA8A2B3Q24240020-9E7F3256-7849-4248-9712-D2FADD918941Q24240260-D11F448E-789C-4F5B-AAA0-2D179A373BC1Q24240433-B4486AC0-C072-4E97-80CB-2A2E8C539316Q24240500-1B99D996-AB48-431B-9A48-6DBC8F32A7EFQ24240919-8159C820-CBD6-4D6C-B027-6A1B14FB03ADQ24240989-79EDF6D9-BF97-4973-8E53-F5BD95C4BA7EQ24241138-8F1CB247-F4FE-4628-8F8D-97854BF74D4AQ24241511-F0D3042E-E287-4C61-B44A-D9AD633319FDQ24241594-B60BBA2A-2356-45F3-BF75-0745EB3403F9Q24241656-2F2A7504-5DDE-4B05-97FE-4B78AC3AD0F8Q24243368-4A73181C-9362-4292-A8E6-BE73BED2D92FQ24244488-7BF3AE4F-3D8B-45A2-B2DD-356B1DACBA33Q24244590-7FB88A54-1084-45E3-BDCD-2F37EABB2CD1Q24244629-6A64FD01-60DC-4EF7-BBED-1A776D773A5AQ24244636-A65E4535-E66B-45C4-B8B9-EF06A4D9426DQ24244791-A8A88736-CD99-4466-B4E0-0144F5EBB058Q24244899-C6F5DC86-1B66-4A4F-9957-9DB7E7A491FAQ24244956-5BBFE893-A7A0-4C99-89F8-66B79A225029Q24244994-827019CD-DA05-4122-93FD-599157316545
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Katja Komossa
@ast
Katja Komossa
@en
Katja Komossa
@es
Katja Komossa
@sl
type
label
Katja Komossa
@ast
Katja Komossa
@en
Katja Komossa
@es
Katja Komossa
@sl
prefLabel
Katja Komossa
@ast
Katja Komossa
@en
Katja Komossa
@es
Katja Komossa
@sl